The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis.

Yoshiya Tanaka,Tatsuya Atsumi,Masato Okada,Tomoya Miyamura,Tomonori Ishii,Susumu Nishiyama,Ryutaro Matsumura,Nobuya Hayashi,Gabriel Abreu,Raj Tummala,Eric F Morand,Tsutomu Takeuchi

Modern rheumatology（2023）

引用 3|浏览21

暂无评分

摘要

The efficacy and safety of anifrolumab 300 mg in Japanese patients with SLE was consistent with the demonstrated clinical profile of anifrolumab for the overall TULIP-2 population.

查看译文

关键词

Systemic lupus erythematosus,anifrolumab,treatment

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要